33.8 C
Vientiane
Sunday, June 8, 2025
spot_img
Home Blog Page 783

Together AI Raises $305M Series B to Scale AI Acceleration Cloud for Open Source and Enterprise AI

Funding will accelerate Together AI’s leadership as the preferred AI Cloud for building modern AI applications with open source models, and for training frontier models with its large-scale deployment of NVIDIA Blackwell GPUs.

SAN FRANCISCO, Feb. 21, 2025 /PRNewswire/ — Together AI, the leading AI Acceleration Cloud, today announced a $305 million Series B investment led by General Catalyst and co-led by Prosperity7. The round saw participation from a distinguished group of global institutional and strategic investors including Salesforce Ventures, DAMAC Capital, NVIDIA, Kleiner Perkins, March Capital, Emergence Capital, Lux Capital, SE Ventures, Greycroft, Coatue, Definition, Cadenza Ventures, Long Journey Ventures, Brave Capital, Scott Banister, and technology pioneer John Chambers.

The funding round, which values the company at $3.3 billion, arrives as Together AI unveils plans for an unprecedented expansion of its AI Acceleration Cloud, with plans for large deployment of NVIDIA Blackwell GPUs. This strategic investment will further accelerate Together AI’s position as the leading end-to-end platform for building with open source models. Together AI’s enterprise-grade inference and fine-tuning capabilities have already transformed how over 450,000 AI developers, AI-native companies, and global enterprises like Salesforce, Zoom, SK Telecom, Hedra, Cognition, Zomato, Krea, Cartesia, and The Washington Post build modern AI applications.

“Vipul and team have built an incredible tech platform and business, emerging as a dominant player in AI infrastructure in less than two years. I was introduced to them when I invested in their first angel round and have witnessed firsthand the evolution of a product that, today, many Fortune 100 clients use to train, finetune, and run inference on models at scale,” said Marc Bhargava, managing director at General Catalyst. “Together AI’s mission to be the full stack AI cloud is truly inspiring, and General Catalyst brings the go-to-market expertise and ambition to supercharge this goal.”

Open source models like DeepSeek-R1 and Meta’s Llama have emerged as formidable alternatives to proprietary solutions, marking a decisive shift in the AI landscape. Together AI has established itself as the definitive platform powering this transformation for developers, AI-native companies, and global enterprises to leverage open source AI with unrivaled speed and efficiency. Together AI delivers the fastest DeepSeek-R1 and Llama inference at production scale through its secure, private infrastructure and research innovations.

“AI is transforming every industry, creating unprecedented efficiencies and enabling entirely new classes of products. We have built a cloud company for this AI-first world — combining state-of-the-art open source models and high performance infrastructure, with frontier research in AI efficiency and scalability,” said Together AI CEO Vipul Ved Prakash. “Our AI Acceleration Cloud uniquely provides organizations with the performance, security, and functionality required to train frontier models and build production-scale AI applications with incredible cost efficiency. With this investment, we will accelerate our mission to make open source AI accessible for AI developers and customers globally.”

Together AI’s platform uniquely spans the entire AI lifecycle, delivering enterprise-grade inference solutions; training and fine-tuning for frontier foundational models; agentic workflows with built-in code interpretation; and synthetic data generation. It enables organizations to build complete AI applications with the performance, security, accuracy, and model ownership that enterprises demand. Supporting over 200 open source models across all modalities — chat, image, audio, vision, code, and embeddings — the platform is powered by Together AI’s proprietary Inference engine and built on research innovations including FlashAttention-3 kernels and advanced quantization techniques. It delivers 2-3x faster inference than today’s hyperscaler solutions.

The company continues to reshape the AI infrastructure landscape with 200 MW of secured power capacity and is deploying optimized clusters of NVIDIA Blackwell GPUs across multiple data centers in North America. Together AI’s partnership with Hypertec to co-build a cluster of 36,000 NVIDIA GB200 NVL72 GPUs further cements its position at the forefront of AI Cloud providers. At the heart of this infrastructure lies the Together Kernel Collection, a breakthrough in AI system optimization developed under the leadership of Chief Scientist Tri Dao, creator of FlashAttention. This proprietary technology stack delivers 24% faster training operations while significantly reducing costs for customers like Pika Labs.

“Recent developments in open source AI illustrate the importance of Together AI’s work in making access to models like these secure, accessible, and powerful for organizations here in the U.S. and around the world,” said Prosperity7 Ventures Managing Director Abhishek Shukla. “Together AI’s ability to do this while accelerating the process, increasing efficiencies and reducing costs makes Together AI an exceptional resource for even large, global businesses.”

Together AI’s research lab continues to pioneer breakthrough methods at the intersection of AI and systems research, with open source contributions like Mixture of Agents, Medusa, Sequoia, Hyena, and Mamba driving innovation across the industry.

The company’s leadership position has been reinforced by milestone achievements at an extraordinary pace. In 2024 alone, Together AI grew its user base to over 450,000 AI developers, and has collaborated with Dell, Hypertec, NVIDIA and Meta. It deployed DeepSeek models in North American data centers with full opt-out privacy controls, launched the Together Enterprise Platform and AWS Marketplace availability, and partnered with Cartesia to enable ultra-low latency voice AI through Sonic model integration. Together AI recently acquired CodeSandbox with plans to integrate its capabilities directly into Together AI for built-in code interpretation – an industry first. The company also strengthened its leadership team with key hires, including go-to-market veteran Kai Mak as CRO, and research pioneer James Zou.

About Together AI

Together AI, the leading AI Acceleration Cloud, empowers developers and enterprises to train, fine-tune and run inference for generative AI models — delivering unparalleled performance, control, and cost-efficiency. The Together AI Platform supports a comprehensive range of top open source and custom models across multiple modalities, while offering flexible deployment options with the highest levels of privacy and security. Committed to advancing the frontier of AI through open collaboration, innovation and transparency, Together AI ensures that powerful AI systems remain accessible and flexible while creating optimal outcomes for society. To start fine-tuning and running the world’s best open source models, visit together.ai.

Media Contact
Rajan Sheth, CMO, Together AI
press@together.ai

Autoliv publishes its Annual and Sustainability Report for 2024

STOCKHOLM, Feb. 21, 2025 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) (SSE: ALIV.sdb), the worldwide leader in automotive safety systems, has filed with the Securities and Exchange Commission (SEC) its 2024 Annual Report on Form 10-K as well its annual sustainability report, filed together with the 10-K as an Annual Report to Shareholders (ARS).

Both the Form 10-K and ARS are available at www.sec.gov and www.autoliv.com

Autoliv has also filed the same reports with the Swedish Financial Supervisory Authority – Finansinspektionen.

Shareholders can receive a hard copy of the complete audited financial statements free of charge by e-mailing their request to: ir@autoliv.com

Inquiries: 

Investors & Analysts: ir@autoliv.com, Anders Trapp, Tel +46 709 578 171, Henrik Kaar, Tel +46 709 578 114

Media: media@autoliv.com, Gabriella Etemad, Tel +46 70 612 64 24, Emelie Ericson, Tel +46 70 957 81 35

About Autoliv

Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2024, our products saved approximately 37,000 lives and reduced around 600,000 injuries.

We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 65,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2024 amounted to $10.4 billion. For more information go to www.autoliv.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/autoliv/r/autoliv-publishes-its-annual-and-sustainability-report-for-2024,c4108316

The following files are available for download:

https://mb.cision.com/Main/751/4108316/3277971.pdf

Autoliv_Annual_Sustainability_Report_10K_F_2024

https://mb.cision.com/Main/751/4108316/3277972.zip

A23RUXWKASG834LTMK28-2024-12-31-0-en.zip

https://mb.cision.com/Public/751/4108316/b88346ee8422028a.pdf

ALV Release Annual Report 2024 on Form10K eng

Bestqool Unveils Four-Wavelength Pro Series and Second-Gen Mobile Stand at Original Price

NEW YORK, Feb. 21, 2025 /PRNewswire/ — In a recent announcement, Bestqool is upgrading both the Pro100 and Pro200 to the four-wavelength configuration (630 nm, 660 nm, 850 nm, 940 nm) as the Pro 300, without increasing the price. Apart from this upgrade, Bestqool has also introduced a second-gen light mobile stand that is more controllable and powerful than its predecessor.

Without raising the price, Bestqool updates the Pro100 and Pro200 with a four-wavelength availablity (630, 660, 850, and 940 nm). In addition to this improvement, Bestqool has unveiled a second-generation mobile stand that is stronger and easier to manage.
Without raising the price, Bestqool updates the Pro100 and Pro200 with a four-wavelength availablity (630, 660, 850, and 940 nm). In addition to this improvement, Bestqool has unveiled a second-generation mobile stand that is stronger and easier to manage.

Bestqool is one of the earliest brands in the red light therapy industry, pursuing innovation in product development to meet the emerging needs in health and wellness. These new products further demonstrate how Bestqool is committed to transforming lives by ensuring people have access to high-quality red light therapy at home.

Two New Wavelengths Unlocking Diverse Medical Benefits

The Pro100 and Pro200 were initially available with two wavelengths, 660 nm and 850 nm, which assist in inflammation reduction and blood circulation. Two new wavelengths have been added with the recent upgrade —630 nm and 940 nm. These new additions stretch the spectrum and make the devices more versatile and able to cater to a wider range of consumer needs.

  • The red light of 630 nm has a better effect on super shallow skin layers, can promote skin repair, and improve skin quality.
  • 940 nm near-infrared light has better penetrating ability, which can penetrate deep tissues, relieve chronic pain, and improve joint function.

For users, the availability of these two wavelengths adds more effective therapies targeting multiple pain points and conditions. From mood improvement to ocular fatigue relief, hair growth support, cognitive function aid, and energy and immunity boosting, Bestqool’s professional-grade apparatus allows users to physically and mentally lead a healthier, more powerful existence that enables them to live with greater enjoyment in today’s speedily changing world.

Upgraded mobile stand and powerful panel light ≠ heavy and clumsy

Bestqool is dedicated to improving user experience, which is evident from their second-generation mobile stand. This stand provides easy adjustment for large-volume red light devices during home therapy sessions, enhancing safety and comfort while performing therapy. 

Key Upgrades:

  • Less weight: Easy to handle and carry.
  • More Robust: Designed to withstand the rigors of commercial use.
  • Customer friendly: Better coordination between the customer and the mounted equipment.

The 2nd Gen mobile stand is also compatible with 99% of the red light therapy products available today; with its help, even users of other brands devices can have a higher level of use experience. The refined stand facilitates the setup of multiple devices, producing an enjoyable and flexible experience for users.

Cost Effectiveness: Major Benefit for Customers

One of the standout features of the Pro Series upgrade is that despite adding two other wavelengths, Bestqool has not increased the price of the Pro100 and Pro200. The upgrade ensures that consumers can access cutting-edge, multi-band therapy at the same price level, making it one of the most cost-effective solutions in the world of red light therapy.

Also, users don’t have to buy multiple devices for their needs. With the updated Pro Series, one device can meet a variety of needs, spanning post-workout recovery, muscle and joint pain relief, skin repair, and enhanced cognitive function. This flexibility allows individuals to explore their health with greater accessibility and cost-effectiveness.

The Ingenious Technology Behind the Upgrade

The upgraded Pro100 and Pro200 are designed to produce the best results possible, according to the R&D team at Bestqool, who has reportedly left no stone unturned. The following improvements were done:

  • Optimized Spectrum Ratio: The spectrum ratio of 630 nm, 660 nm, 850 nm and 940 nm has been finely tuned to achieve optimal synergy of the four wavelengths. This maintains that each of the wavelengths is colluding to provide maximum therapeutic effects without wasting any energy. This results in a more powerful and efficient device.
  • Dual-Chip Lamp Beads: The Pro100 and Pro200 now employ an innovative dual-chip lamp bead design. This enables the devices to work at the new wavelengths while still providing stable, reliable output. This improves performance without sacrificing longevity or power efficiency of the device.
  • Upgraded Circuit / Improved Heat Dissipation: The devices now feature two additional wavelengths, which require higher power input, leading to excessive heat generation. To ensure the devices stay safe and efficient even at high output conditions, Bestqool has adopted an upgraded version of the circuit design and heat dissipation system. With this upgrade, it ensures smooth and durable performance of Pro Series products for users.
  • Increased Device Longevity: The technical features of the Pro Series contribute to the longevity of the devices. Optimized parts in addition to increased heat dissipation give users the reassurance that these new models will provide safe and effective operation for many years with no performance degradation.

About Bestqool

With a commitment to providing high-quality red light therapy solutions that are affordable and accessible to all, Bestqool invests significantly in R&D to ensure each product meets the highest standards of both quality and performance. This dedication to constant development and service quality has earned them countless loyal customers as the franchise continues to set the standard in the wellness industry.

Market impact and availability

There are two main purchasing channels for the products: Amazon and the official website of Bestqool. With warehouses in Europe, America, and Asia, Bestqool assures effective and reliable services to all its customers globally. Additionally, Bestqool offers up to a three-year warranty on its products. This commitment to after-sales service reflects the company’s confidence in its quality and helps strengthen relationships with customers.

Contact
For media contact and inquiries, please contact
Giselle
Email: marketing@Bestqool.com 

INMOTION Unveils V9: A New Benchmark for Electric Unicycles

SHENZHEN, China, Feb. 21, 2025 /PRNewswire/ — INMOTION Technologies Co., Ltd., a global leader in intelligent personal mobility, has officially launched the V9, a groundbreaking electric unicycle that sets a new industry standard. Designed to enhance safety, intelligence, and entertainment, the V9 aims to accelerate the adoption of electric unicycles and further drive the industry’s growth.  

The World’s First UL-Certified Electric Unicycle
The World’s First UL-Certified Electric Unicycle

Enhanced Safety and Intelligence: Redefining Industry Standards

The INMOTION V9 is the world’s first electric unicycle to receive TÜV Rheinland UL2272 certification, ensuring compliance with stringent North American safety standards. Additionally, it is the first unicycle equipped with the RideConnect function, featuring 4G remote locking, ride tracking, and 24/7 online monitoring—even when the device is powered off. With app-based remote access, users can check battery health, adjust ride modes, and enjoy a safer, more convenient riding experience.

Unparalleled Riding Experience: Lightweight and High-Performance

Built for both comfort and performance, the V9 features the Nimbus Air suspension system, providing smooth rides on various terrains. It is powered by high-end Samsung battery cells, rigorously tested under extreme temperatures, and managed by an advanced Battery Management System (BMS) to ensure safety and longevity. The Raptor M controller, combined with the Ultra-Control balance system, delivers precise, stable power output for optimal ride control.

Entertainment on the Go: Music, Lights, and More

Beyond performance, the V9 enhances the riding experience with Light-Pulse ambient lighting, offering 256 colors and customizable lighting effects to match any mood or style. The built-in high-fidelity stereo dual speakers support group ride audio sync, allowing riders to enjoy music with your friends together and create an immersive outdoor concert-like experience.

Driving Industry Growth: Making Electric Unicycles More Accessible

As a pioneer in the electric unicycle industry, INMOTION is committed to expanding market adoption and educating consumers.
“The V9 is not just a product—it’s a major step toward making electric unicycles a mainstream mode of transportation,” said INMOTION’s CEO, WangYu. “We aim to break down barriers and make this technology more accessible. To achieve this, we have prioritized industry promotion, user education, and market expansion over short-term profits.”

Shaping the Future of Micro-Mobility

With its cutting-edge technology, superior quality, and user-centric design, INMOTION continues to redefine industry standards for electric unicycles. The launch of the V9 is not just an innovation—it’s a commitment to driving the future of micro-mobility and enabling more riders to experience the freedom and excitement of electric unicycles.

Watch the launch event: https://www.youtube.com/@INMOTIONSCV

Know more about INMOTION V9: https://bit.ly/4b70Gga

About INMOTION

Founded in 2012, INMOTION Technologies Co., Ltd. is a global leader in short-distance transportation, specializing in electric unicycles, e-scooters, and micro-mobility solutions. With a strong focus on innovation and quality, INMOTION is dedicated to transforming personal transportation and providing users with smarter, more convenient ways to move.

BROADCOM FOUNDER HENRY SAMUELI IS 2025 IEEE MEDAL OF HONOR LAUREATE, FIRST RECIPIENT OF NEWLY INCREASED $2 MILLION PRIZE, AMONG THE WORLD’S MOST PRESTIGIOUS TECHNOLOGY-FOCUSED AWARDS

Samueli Transformed How Society Communicates, Connects, and Does Business Through His Pioneering Research and Commercialization of Broadband Communication and Networking Technologies

PISCATAWAY, N.J., Feb. 21, 2025 /PRNewswire/ — IEEE, the world’s largest technical professional organization advancing technology for humanity, today announced that Henry Samueli is the 2025 IEEE Medal of Honor Laureate and the first recipient of its $2 million monetary prize. This highest of IEEE awards is bestowed on Samueli, an IEEE Fellow, in recognition of his pioneering research and advances in developing and commercializing analog and mixed signal communications systems circuits, which led to the explosive growth of broadband communication, wired and wireless networking technologies used today. A prominent philanthropist, Samueli is also honored for his significant support for science, technology, engineering, and math (STEM) education.

“IEEE Medal of Honor Laureate Henry Samueli’s vision and communications technology innovations spurred the development of products used by nearly every person around the world,” said 2025 IEEE President and CEO Kathleen Kramer. “From the billions of consumer smart phones, set-top boxes and tablets to laptops, and IoT devices, Samueli created new and novel ways to power connections and unite humanity.”

As a UCLA electrical engineering professor, Samueli used his knowledge to conceive digital signal processing architectures for broadband communications chips, and after founding Broadcom, built the world’s first digital cable set-top-box modem chipset. This laid the foundation for delivering UltraHD, HDTV and high quality video streaming to the home, and today, the company is a global leader in semiconductor technologies for wired and wireless communications.

“Through broadband, Henry Samueli helped revolutionize how the world is connected, fostered cultural and economic paradigm shifts of countless industries, and positively changed how we do everything today,” added K. J. Ray Liu, Chair of the Ad Hoc Committee on Raising the Prestige of IEEE Awards and 2022 IEEE President and CEO. “In addition, his prolific philanthropy has deeply impacted many lives for the better – from generous support of STEM education to a pledge to give away the majority of his money during his lifetime. These contributions are exemplary for technologists, modeling the impact they can have not just on the world they live in, but for those who follow them.”

Additional information about the 2025 IEEE Medal of Honor Laureate Henry Samueli, as well as the history of the prize can be found at:

The 2025 IEEE Medal of Honor, as well as additional high-profile IEEE awards, will be presented at the 2025 IEEE Honors Ceremony on April 24, 2025, which will for the first time be held in Tokyo, Japan.

About IEEE Awards
For more than a century, the IEEE Awards Program has served as the world’s top peer-recognition program, acknowledging preeminent leaders and visionaries in science, technology, and engineering advancement. Through the program, IEEE recognizes pivotal contributions in fields of interest to IEEE that advance technology for the benefit of humanity.

For more information, please visit, or follow IEEE Awards on X|Twitter, Facebook, and LinkedIn.

About IEEE
IEEE is the world’s largest technical professional organization and a public charity dedicated to advancing technology for the benefit of humanity. Through its highly cited publications, conferences, technology standards, and professional and educational activities, IEEE is the trusted voice in a wide variety of areas ranging from aerospace systems, computers, and telecommunications to biomedical engineering, electric power, and consumer electronics. Learn more at https://www.ieee.org.

Contact:
Monika Stickel
+1 732 562 6027
m.stickel@ieee.org 

Francine Tardo
+1 732 465 5865
f.tardo@ieee.org

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA

  • YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1
  • First-in-class novel PTH replacement therapy
  • Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval

SINGAPORE, Feb. 21, 2025 /PRNewswire/ — Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic Goods Administration (TGA), “for the treatment of chronic hypoparathyroidism in adults”.1,2 YORVIPATH was granted an Orphan Drug Designation and assessed through the TGA’s Priority Review pathway.3,4 It is the first and only medicine to be listed on the Australian Register of Therapeutic Goods (ARTG) for the treatment of chronic hypoparathyroidism.

Hypoparathyroidism is a rare, complex endocrine disease, affecting an estimated 6.4-37 per 100,000 people globally.5,6 It is an endocrine disorder in which the production of parathyroid hormone (PTH) by the parathyroid glands is abnormally low or absent, causing low levels of calcium (hypocalcaemia) and high levels of phosphorous (hyperphosphataemia) in the blood.7,8 This impacts proper functioning of nerves and muscles, leading to weakness, muscle spasms or cramps, headaches, hair loss, numbness or tingling, and memory problems.8,9 Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extraskeletal calcifications, and cognitive impairment.10

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical need for Australian adults diagnosed with chronic hypoparathyroidism.

“Until now, the only treatment option for adults with chronic hypoparathyroidism has been conventional therapy with calcium and active vitamin D supplementation to keep blood calcium levels normal,” said Professor Ebeling. “While these treatments help to manage the symptoms of hypoparathyroidism, they do not address the underlying deficiency of PTH and contribute to the significant pill burden for patients.”

“The lack of effective therapeutic options has been an urgent medical need in this area, and the local approval of YORVIPATH represents an important advance in the treatment of chronic hypoparathyroidism in Australia,” said Professor Ebeling. 

YORVIPATH is a first-in-class PTH replacement therapy. A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed to provide PTH levels in the physiological range for 24 hours/day.11

YORVIPATH’s approval in Australia was supported by the results of Ascendis Pharma’s Phase 3 PaTHway trial, a 26-week randomised, double-blind, placebo-controlled study with a 156-week open-label extension, published in the Journal of Bone and Mineral Research.12 Involving 84 adults with chronic hypoparathyroidism, the clinical trial demonstrated the efficacy, safety and tolerability of YORVIPATH as a once-daily PTH replacement therapy.

Data from the pivotal trial showed 93% (57/61) of YORVIPATH-treated patients achieved independence from both active vitamin D and therapeutic doses of elemental calcium, which was associated with a clinically meaningful reduction in their daily pill burden.12

The safety analysis demonstrated YORVIPATH was generally well-tolerated, with the most frequently reported adverse reactions being injection site reactions (21.6%), headache (18.7%), and paraesthesia (13.7%).2

In addition to the significant short-term and long-term medical complications of chronic hypoparathyroidism, individuals diagnosed with the condition also experience reduced health-related quality of life, including the negative impact of symptoms on their daily life and work productivity.12

Chief Executive Officer of the Australian Thyroid Foundation (ATF), Beverley Garside, acknowledged the significance of the TGA approval in offering adults living with chronic hypoparathyroidism the opportunity to improve their health and wellbeing. However, she reinforced that this is not the time for complacency, as it is just the first step towards securing subsidised access to an important new treatment option for this community.

“As the leading national voice for good thyroid health in Australia, the ATF recognises the importance of the TGA registration of YORVIPATH as a new treatment option for the hypoparathyroid community. While this is positive news, it is only the first step,” said Ms Garside. “For adults diagnosed with chronic hypoparathyroidism to truly benefit from this new treatment, it is essential they have the option of subsidised and affordable access to YORVIPATH through the Pharmaceutical Benefits Scheme as quickly as possible.”

YORVIPATH is being made available in Australia by Specialised Therapeutics (ST), under an exclusive distribution agreement with global biopharmaceutical company Ascendis Pharma A/S that covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. The Australian registration of YORVIPATH follows approvals issued to Ascendis Pharma by the United States Food and Drug Administration (US FDA)13 in August 2024 and the European Medicines Agency (EMA)14 in November 2023.

“The Australian approval of YORVIPATH reflects our values and dedication to applying science to help address the significant unmet medical needs expressed by the hypoparathyroidism community,” said Roy Khoury, Vice President, Head of International Markets at Ascendis Pharma. “We are pleased to partner with Specialised Therapeutics to broaden access to this innovative therapy, based on our TransCon technology, which offers a new approach to the treatment of this often-debilitating rare disease.”

ST Chief Executive Officer, Mr Carlo Montagner, said the approval of YORVIPATH was a meaningful milestone, but the company would not stop until it achieved reimbursement for eligible Australians with hypoparathyroidism through the Pharmaceutical Benefits Scheme (PBS).

“We are proud to have brought the first and only TGA-registered treatment for chronic hypoparathyroidism to Australians living with the condition so rapidly following the recent FDA and EMA approvals,” said Mr Montagner. “Chronic hypoparathyroidism has considerable and life-long wide-ranging impacts on these individuals and we are committed to working with the local hypoparathyroidism community and the Australian Government to ensure YORVIPATH is accessible to eligible patients through the PBS at the earliest opportunity.”

YORVIPATH will be reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) at its first meeting of the year, to be held from 12-14 March 2025. YORVIPATH will be made available for prescribing in Australia once it has been listed on the PBS.

PBS Information: YORVIPATH is not listed on the Pharmaceutical Benefits Scheme (PBS).

About Specialised Therapeutics

Founded in 2007, Specialised Therapeutics is the region’s largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company’s broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA).

Additional information can be found at www.stbiopharma.com

About Ascendis Pharma

Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit: ascendispharma.com to learn more.

About Hypoparathyroidism10

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestines. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes.

About PaTHway12

The PaTHway trial was a double-blind, placebo-controlled, 26-week, Phase 3 study that assessed the efficacy and safety of PTH replacement therapy with palopegteriparatide for individuals with hypoparathyroidism. Participants (n=84) were randomised 3:1 to once-daily palopegteriparatide (initially 18 μg/d) or placebo, both co-administered with conventional therapy.

The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin-adjusted serum calcium levels (8.3–10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and ≤600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. At week 26, 79% (48/61) of participants treated with palopegteriparatide versus 5% (1/21) with placebo met the composite primary efficacy endpoint (p < 0.0001). Additionally, 93% (57/61) of participants treated with palopegteriparatide achieved independence from conventional therapy. Palopegteriparatide treatment normalised mean 24-hour urine calcium. Overall, 82% (50/61) treated with palopegteriparatide and 100% (21/21) with placebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug-related withdrawals occurred.

About YORVIPATH® (palopegteriparatide)

YORVIPATH® (palopegteriparatide, developed as TransCon™ PTH) is a once-daily prodrug providing sustained release of active PTH. It was approved by the European Union as a parathyroid hormone (PTH) replacement therapy for the treatment of adults with chronic hypoparathyroidism15 and the United States for the treatment of hypoparathyroidism in adults13. Treatment should be initiated and monitored by physicians or qualified healthcare professionals experienced in the diagnosis and management of patients with hypoparathyroidism.

Yorvipath® is a registered trademark of Ascendis Pharma A/S (NASDAQ: ASND).

References:

  1. Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG). Available at: https://www.tga.gov.au/australian-register-therapeutic-goods. [Accessed Dec 2024].
  2. YORVIPATH (palopegteriparatide) AU Product Information.
  3. Therapeutic Goods Administration. Prescription medicine determinations and designations: Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd) – Orphan drug designation. Available at: https://www.tga.gov.au/resources/designations-determinations/notice-palopegteriparatide-specialised-therapeutics-pharma-pty-ltd. [Accessed Dec 2024].
  4. Therapeutic Goods Administration. Prescription medicine determinations and designations: Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd) – Priority review. Available at: https://www.tga.gov.au/resources/designations-determinations/notice-palopegteriparatide-specialised-therapeutics-pharma-pty-ltd-0. [Accessed Dec 2024].
  5. Siggelkow H, Pacaud D, et al. Clin Endocrinol (Oxf). 2020;92(2).
  6. Bjornsdottir S, Sikjaer T, et al. J Bone Miner Res. 2022;37(12).
  7. Australian Thyroid Foundation. Thyroid Facts: Parathyroid Glands – Hypoparathyroidism. Available at: https://thyroidfoundation.org.au/Parathyroid-Glands [Accessed Dec 2024].
  8. National Organization for Rare Disorders. Disease Overview: Hypoparathyroidism – Symptoms, Causes, Treatment, 14 August 2024. Available at: https://rarediseases.org/rare-diseases/hypoparathyroidism/ [Accessed Dec 2024].
  9. Endocrine Society. Endocrine Library: Patient Resources; Hypoparathyroidism, 24 January 2022. Available at: https://www.endocrine.org/patient-engagement/endocrine-library/hypoparathyroidism [Accessed Dec 2024].
  10. Bilezikian JP. J Clin Endocrinol Metab. 2020;105(6):1722-1736. doi:10.1210/clinem/dgaa113.
  11. YORVIPATH (palopegteriparatide) US Prescribing Information.
  12. Khan AA, Bilezikian JP, Cusano NE, et al. J Bone Miner Res. 2023;38(1). 
  13. US Food and Drug Administration. FDA approves new drug for hypoparathyroidism, a rare disorder, 9 August 2024. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder [Accessed Dec 2024].
  14. European Medicines Agency. Yorvipath: Palopegteriparatide, 17 November 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/yorvipath [Accessed Dec 2024].
  15. YORVIPATH (palopegteriparatide).EU Summary of Product Characteristics.

 

NAVER D2SF-Backed PranaQ® Receives FDA 510(k) Clearance for TipTraQ, an AI-Enabled Home Sleep Apnea Test

SEOUL, South Korea, Feb. 21, 2025 /PRNewswire/ — PranaQ, backed by NAVER D2SF continues to push the boundaries of AI-powered healthcare solutions. NAVER D2SF, NAVER’s corporate venturing arm, actively collaborates with startups to drive innovation and sustainable growth. This investment underscores NAVER D2SF’s commitment to advancing AI and healthcare technologies on a global scale.

PranaQ, a pioneer in AI-powered sleep diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TipTraQ, a single-point-of-contact home sleep apnea test wearable that provides comprehensive sleep and respiratory insights with minimal sleep disruption. With FDA clearance, PranaQ is set to launch nationwide, making TipTraQ available to sleep clinics, telehealth providers, and hospitals.

TipTraQ is a compact wearable that uses advanced biosensors and AI algorithms to detect sleep apnea events and analyze sleep architecture with clinical-grade accuracy. The device enables patients to undergo testing from the comfort of their homes, reducing barriers to diagnosis and improving patient compliance.

The wearable includes a charging case and supports remote data transfer, so patients don’t need to return the device after each night. This makes it ideal for seamless multi-night testing and continuous treatment monitoring, giving healthcare providers a comprehensive and longitudinal view of patients’ sleep at home.

In addition to its comprehensive sleep parameters, TipTraQ is cleared for its ability to identify sleep apnea severity cutoffs of 5 (mild), 15 (moderate), and 30 (severe) under both the AASM 1a and 1b rules, delivering actionable insights to support well-informed clinical decisions.

“Receiving FDA clearance for TipTraQ is a significant milestone in our mission to revolutionize sleep diagnostics and monitoring,” said Jerry Chen, CEO of PranaQ. “With millions of undiagnosed sleep apnea sufferers, TipTraQ enables accessible and reliable at-home testing, helping more people receive timely diagnosis and treatment.”

Meanwhile, TipTraQ’s accuracy has been validated through clinical trials across North America and Asia, including Duke University Hospital and UCSF, demonstrating high sensitivity and specificity compared to gold-standard polysomnography (PSG).

It also achieves exceptional SpO₂ accuracy across all skin tones. By addressing a well-documented limitation in pulse oximetry, it ensures consistent and reliable nocturnal oxygen monitoring, further enhancing its effectiveness in diagnosing sleep apnea and prioritizing health equity.

Aatif M. Husain, MD, Chief of Epilepsy, Sleep, and Clinical Neurophysiology at Duke University Hospital, commented, “TipTraQ represents a breakthrough in home-based sleep apnea testing. By integrating AI-driven analysis with a user-friendly wearable, this device can significantly improve early detection and treatment accessibility.

About PranaQ

PranaQ is a digital healthcare company that develops wearable medical devices for sleep and breathing disorders. Its products feature AI-based biomedical signal-processing algorithms designed to monitor and analyze health conditions. Founded in 2021 and based in New York City, PranaQ is dedicated to empowering individuals with better knowledge and control over their medical treatments by making diagnostics and monitoring more accessible, efficient, and patient-centered.

For more information on TipTraQ, visit www.pranaq.com or email contact@pranaq.com.

About NAVER D2SF

NAVER D2SF is NAVER’s corporate venturing(CV) arm, taking on greater challenges and fostering more sustainable growth through collaboration with startups. Founded in 1999, NAVER is a rare example of a domestic search engine that has maintained its top position in South Korea for over 20 years and has established a strong presence in various business sectors including commerce, content, fintech, and cloud services. In addition to its own offerings, NAVER is building a strong global business portfolio through partnerships with industry-leading companies, including Poshmark, and Wattpad. NAVER recorded sales of KRW 9.6 trillion (USD 6.9 billion) in 2023. At the same time, under the technological vision of D2(For Developers, By Developers), we are actively developing new technologies and collaboration initiatives to grow into a global tech company.

To learn more, visit https://d2startup.com/en.

Oregon Tool, Inc. Announces New Money and Recapitalization Transactions to Bolster Liquidity and Optimize Capital Structure

  • $150 million of new money to boost liquidity,

  • reduction of pre-transaction debt by over $75 million, and

  • extended maturities dates to Q4 2029

PORTLAND, Ore., Feb. 20, 2025 /PRNewswire/ — Oregon Tool, Inc. (the “Company”) a global leader and manufacturer of professional-grade cutting tools for forestry, lawn and garden; farming, ranching and agriculture; and concrete cutting and finishing industries announced today the closing of three separate, highly beneficial financing transactions (the “Transactions”). The Transactions were supported by a substantial majority of the capital structure, including 100% of RCF lenders, approximately 83% in amount of existing term loans, and approximately 81% in amount of existing unsecured notes. Subsequent to the Transactions, the Company expects to make one or more exchange offers to additional holders of existing terms loans and existing unsecured notes. The Transactions provide material benefits to the Company.

On February 18, 2025, the Company caused its newly formed subsidiary, Oregon Tool Lux LP, a Luxembourg entity (the “NewCo”), to issue approximately $156 million principal amount of new first lien debt, in the form of term loans (“NewCo First Lien Term Loan”). On the same day, the Revolving Credit Facility lenders exchanged, at par, into a new first lien Revolving Credit Facility, at NewCo (the “New Revolver”). On February 19, 2025, an ad hoc group of Term Loan lenders (“Term Loan AHG”) and an ad hoc group of holders of Term Loans and Notes (“Crossholder AHG”) extended the maturity of their term loans to October 2029. On February 20, 2025, Term Loan AHG and Crossholder AHG lenders, at the Company’s election, (i) refinanced or committed to refinance, at a discount, all existing Term Loans maturing in October 2029 and (ii) committed to exchange all notes held by the Term Loan AHG and Crossholder AHG members, into a mix of new second lien term loans (“Second Lien Term Loan”) and new third lien notes (“Third Lien Notes”) at NewCo. The New Revolver, the NewCo First Lien Term Loan, Second Lien Term Loan, and Third Lien Notes, have maturities of October 15, 2029. In addition, the Company’s existing ABL lenders extended the maturity of the Company’s ABL Credit Facility to October 15, 2029.

In connection with the Transactions, the participating lenders consented to the adoption of certain amendments to the existing term loan facility, which are now effective. Among other modifications, the amendments eliminated restrictive covenants in the existing debt.

As a result of the Transactions, the Company increased its liquidity by approximately $150 million (before giving effect to the use of proceeds thereof) and reduced its pre-transaction debt obligations by over $75 million.

“This transaction positions the Company for long-term success and benefits our key stakeholders,” said Terry Hames, President and CFO of Oregon Tool, Inc. “The transaction deleverages our balance sheet through discount capture, provides critical liquidity for our operational needs through $150 million of new money, and extends maturities to Q4 2029. We are in position to continue investing in our strategic initiatives to develop innovative solutions for our customers, execute on identified operational efficiencies, and drive long-term profitable growth.”

PJT Partners LP served as financial advisor and Milbank LLP served as legal counsel to the Company. Perella Weinberg Partners LP served as financial advisor and Davis Polk & Wardwell served as legal counsel to the Term Loan AHG. Lazard served as financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to the Crossholder AHG. Cahill, Gordon & Reindel served as legal counsel to RCF and ABL lenders.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any offer, solicitation or sale of securities by the Company in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Oregon Tool, Inc.

Oregon Tool, Inc. is a global, premium-branded, precision-cutting-tool powerhouse platform. The company’s portfolio of brands specializes in professional grade precision cutting tools for forestry, lawn and garden; farming, ranching and agriculture; and concrete cutting and finishing. Headquartered in Portland, Oregon, with a multinational manufacturing and distribution footprint, Oregon Tool, Inc. sells its products in more than 110 countries under the Oregon®, Woods®, ICS®, Pentruder®, Merit®, and Carlton® brands. The company is a global leader in manufacturing of saw chain and guide bars for chainsaws and diamond saw chain for concrete and pipe, a leading manufacturer of agricultural tractor attachments and lawn mower blades, and the leading OEM supplier of first-fit and replacement parts. Learn more at www.oregontool.com

Media Contact

Oregon Tool Communications
communications@oregontool.com